Quick Facts
  • Primary Location:
    Abramson Cancer Center at Penn Medicine
  • Expertise:
    Respiratory Disease
    Pleural Mesothelioma
    Immunotherapy
  • Speciality:
    Interventional Pulmonology
  • Gender:
    Male
  • Language:
    English
  • Med School:
    University of Maryland School of Medicine

Get to Know Dr. Edmund K. Moon

Pulmonologist Dr. Edmund K. Moon focuses on the diagnosis and treatment of diseases that impact the pleural space and the airways, including lung cancer and malignant mesothelioma.

As an associate professor of medicine at the University of Pennsylvania, he has played an important role in helping develop improved forms of immunotherapy for patients. Much of that research involves building on the anti-tumor function of T cells.

Moon works with other doctors in several multidisciplinary specialty programs at Penn Medicine, including medical critical care, interventional pulmonology, mesothelioma and pleural disease, and lung cancer.

He also has expertise in a variety of airway disorders, central airway obstruction, bronchoscopy, autoimmune pleuritis and laser resection of airway tumors.

Contact Dr. Edmund K. Moon
By submitting, you agree to our privacy policy and disclaimer. Our Patient Advocates may contact you via phone, email and/or text.

Specialties of Dr. Edmund K. Moon

  • Asbestosis
  • Pleural mesothelioma
  • Pleurodesis
  • Electromagnetic navigation bronchoscopy
  • Airway stent placement
  • CT scan
  • Immunotherapy
  • Airway disorders

Dr. Edmund K. Moon’s Experience and Medical Education

  • University of Pennsylvania Medicine
  • Hospital of the University of Pennsylvania (Fellowship)
  • Temple University Hospital (Residency)
  • University of Maryland School of Medicine (M.D.)

Awards and Certifications

  • Board certified in pulmonary disease
  • American Medical Association (Member)
  • American Thoracic Society (Member)
  • American College of Chest Physicians (Member)

Publications of Dr. Edmund K. Moon

  • Martinez, M. et al. (2021, January). Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer. OncoImmunology.
  • Quinn, W.J. et al. (2020, December 15). Lactate Limits T Cell Proliferation via the NAD(H) Redox State. Cell Reports.
  • Cramer, G.M. et al. (2020, June 23). Photodynamic Therapy and Immune Checkpoint Blockade. Photochemistry and Photobiology.
  • Moon, E. (2019, May). What pulmonologists need to know about cancer immunotherapy. American Thoracic Society 2019 International Conference.
people watching webinar on computer
Browse Our Free Mesothelioma Webinars
group of people holding money
Access More than $32 Billion in Trust Funds
scientists in laboratory
Find Active Mesothelioma Clinical Trials